EVOLTRA Concentrate for solution for infusion (2020)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Evoltra 1 mg/ml concentrate for solution for infusion.
Qualitative and quantitative composition
Each ml of concentrate contains 1 mg of clofarabine. Each 20 ml vial contains 20 mg of clofarabine. Excipient with known effect: Each 20 ml vial contains 180 mg of sodium chloride. For the full list of ...
Pharmaceutical form
Concentrate for solution for infusion. Clear, practically colourless solution with a pH of 4.5 to 7.5 and an osmolarity of 270 to 310 mOsm/l.
Therapeutic indications
Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated ...
Posology and method of administration
Therapy must be initiated and supervised by a physician experienced in the management of patients with acute leukaemias. Posology Adult population (including elderly) There are currently insufficient data ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Use in patients with severe renal insufficiency or severe hepatic impairment. Breast-feeding (see section 4.6). ...
Special warnings and precautions for use
Evoltra is a potent antineoplastic agent with potentially significant haematological and non-haematological adverse reactions (see section 4.8). The following parameters should be closely monitored in ...
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. However, there are no known clinically significant interactions with other medicinal products or laboratory tests. Clofarabine is not detectably metabolised ...
Fertility, pregnancy and lactation
Contraception in males and females Females of childbearing potential and sexually active males must use effective methods of contraception during treatment. Pregnancy There are no data on the use of clofarabine ...
Effects on ability to drive and use machines
No studies on the effects of clofarabine on the ability to drive and use machines have been performed. However, patients should be advised that they may experience undesirable effects such as dizziness, ...
Undesirable effects
Summary of the safety profile Nearly all patients (98%) experienced at least one adverse event considered by the study investigator to be related to clofarabine. Those most frequently reported were nausea ...
Overdose
Symptoms No case of overdose has been reported. However, possible symptoms of overdose are expected to include nausea, vomiting, diarrhoea and severe bone marrow suppression. To date, the highest daily ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, antimetabolites ATC code: L01BB06 Mechanism of action Clofarabine is a purine nucleoside anti-metabolite. Its antitumour activity is believed to be due ...
Pharmacokinetic properties
Adsorption and distribution The pharmacokinetics of clofarabine were studied in 40 patients aged between 2 to 19 years old with relapsed or refractory ALL or AML. The patients were enrolled into a single ...
Preclinical safety data
Toxicology studies of clofarabine in mice, rats and dogs showed that rapidly proliferating tissues were the primary target organs of toxicity. Cardiac effects were observed in rats consistent with cardiomyopathy ...
List of excipients
Sodium chloride Water for injections
Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Shelf life
3 years. The diluted concentrate is chemically and physically stable for 3 days at 2°C to 8°C and at room temperature (up to 25°C). From a microbiological point of view, it should be used immediately. ...
Special precautions for storage
Do not freeze. For storage conditions after dilution of the medicinal product, see section 6.3.
Nature and contents of container
Type I glass vial with bromobutyl rubber stopper, polypropylene flip-off cap and aluminium overseal. The vials contain 20 ml concentrate for solution for infusion and are packaged in a box. Each box contains ...
Special precautions for disposal and other handling
Special precautions for administration Evoltra 1 mg/ml concentrate for solution for infusion must be diluted prior to administration. It should be filtered through a sterile 0.2 micrometre syringe filter ...
Marketing authorization holder
Genzyme Europe BV, Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands
Marketing authorization number(s)
EU/1/06/334/001 3 vials EU/1/06/334/002 4 vials EU/1/06/334/003 10 vials EU/1/06/334/004 20 vials EU/1/06/334/005 1 vial
Date of first authorization / renewal of the authorization
Date of first authorisation: 29 May 2006 Date of latest renewal: 14 January 2016
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
